1. Adapalene-benzoyl peroxide (Epiduo) for acne. Med Lett Drugs Ther 2009; 51:31.

2. W Ting. Randomized, observer-blind, split-face study to compare the irritation potential of 2 topical acne formulations over a 14-day treatment period. Cutis 2012; 90:91.

3. Clindamycin-tretinoin (Veltin Gel) for acne. Med Lett Drugs Ther 2010; 52:102.

4. Extended-release minocycline (Solodyn) for acne. Med Lett Drugs Ther 2006; 48:95.

5. SE Garner et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2012; Aug 15 (8):CD002086.

6. Isotretinoin (Absorica) for acne. Med Lett Drugs Ther 2013; 55:8.

7. AO Arowojolu et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7:CD004425.

8. EA Arrington et al. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis 2012; 90:83.

9. CB Turowski and WD James. The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatmentresistant acne vulgaris. Adv Dermatol 2007; 23:155.

10. HC Williams et al. Acne vulgaris. Lancet 2012; 379:361.

11. J Fowler et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 2012; 166:633.

12. Low-dose doxycycline (Oracea) for rosacea. Med Lett Drugs Ther 2007; 49:5.

13. KJ Butterwick et al. Laser and light therapies for acne rosacea. J Drugs Dermatol 2006; 5:35.

14. FO Nestle et al. Psoriasis. N Engl J Med 2009; 361:496.

15. Calcipotriene for psoriasis. Med Lett Drugs Ther 1994; 36:70.

16. Calcitriol (Vectical) for mild to moderate plaque psoriasis. Med Lett Drugs Ther 2009; 51:70.

17. A betamethasone-calcipotriene combination for psoriasis. Med Lett Drugs Ther 2006; 48:55.

18. T Mudigonda et al. A review of targeted ultraviolet B phototherapy for psoriasis. J Am Acad Dermatol 2012; 66:664.

19. VM Heydendael et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658.

20. C Ryan et al. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 2010; 63:949.

21. JH Saurat et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558.

22. J Schmitt et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159:513.

23. MH Rustin. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012; 167 (suppl 3):3.

24. CL Leonardi et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014.

25. AS Paller et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358:241.

26. J Bagel et al. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 2012; 67:86.

27. A Menter et al. Arandomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2006; 56:31.

28. A Menter et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106.

29. A Kavanaugh et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976.

30. Ustekinumab (Stelara) for psoriasis. Med Lett Drugs Ther 2010; 52:7.

31. KA Papp et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675.

32. K Reich et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011; 365:1586.

33. BE Strober et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:661.

34. C Ryan et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306:864.

35. T Tzellos et al. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2012; March 8 (epub).

36. K Papp et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380:738.

37. KA Papp et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dosecomparison study. J Eur Acad Dermatol Venereol. 2012 Oct 3 (epub).

38. Tofacitinib (Xeljanz) for rheumatoid arthritis. Med Lett Drugs Ther 2013; 55:1.

39. KA Papp et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167:668.